Abstract
BackgroundThe recruitment of secondary progressive multiple sclerosis (SPMS) patients to the MS-STAT trial (a double-blind randomised placebo-controlled trial of high dose simvastatin) provided an opportunity to evaluate the frequency and...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have